Search research articles
Contact Us
Filters
Showing results (211-220 of 397) with videos related to
Page
of 40
Sort By:
Oncotarget
|
July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
Ishwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
The Oncologist
|
September 26, 2022
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
John D Powderly, Samuel J Klempner, Aung Naing, et al.
Investigational New Drugs
|
November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
David S Hong, Jennifer Hsing Choe, Aung Naing, et al.
ESMO Open
|
November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
Andrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
Scientific Reports
|
February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
Yudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Oncotarget
|
September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
Vikas Dembla, Neeta Somaiah, Pedro Barata, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology
Stephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
Journal for Immunotherapy of Cancer
|
April 19, 2020
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
Coya Tapia, Phyu P Aung, Sinchita Roy-Chowdhuri, et al.
Investigational New Drugs
|
October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
Gerald S Falchook, Stacy Moulder, Aung Naing, et al.
Page
of 40
Search research articles
Search
Showing results (211-220 of 397) with videos related to
Sort By:
Page
of 40
Oncotarget
|
July 13, 2015
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
Ishwaria M Subbiah, Gerald S Falchook, Ahmed O Kaseb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2012
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, et al.
The Oncologist
|
September 26, 2022
Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
John D Powderly, Samuel J Klempner, Aung Naing, et al.
Investigational New Drugs
|
November 27, 2012
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
David S Hong, Jennifer Hsing Choe, Aung Naing, et al.
ESMO Open
|
November 24, 2020
Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
Andrew W Hahn, Omar Alhalabi, Pavlos Msaouel, et al.
Scientific Reports
|
February 22, 2020
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
Yudong Wang, Filip Janku, Sarina Piha-Paul, et al.
Oncotarget
|
September 22, 2018
Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
Vikas Dembla, Neeta Somaiah, Pedro Barata, et al.
Signal Transduction and Targeted Therapy
|
February 23, 2026
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology
Stephanie T Schmidt, Mehmet A Baysal, Siqing Fu, et al.
Journal for Immunotherapy of Cancer
|
April 19, 2020
Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors
Coya Tapia, Phyu P Aung, Sinchita Roy-Chowdhuri, et al.
Investigational New Drugs
|
October 18, 2014
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer
Gerald S Falchook, Stacy Moulder, Aung Naing, et al.
Page
of 40